The CDC, American Thoracic Society & American Lung Association recommend the Mantoux Test as the standard tuberculin skin test. In the United States, the Mantoux Tuberculin Skin Test has been the standard method for detecting latent tuberculosis (TB) infection since the 1930s.1
The skin test is primarily used in two situations. First, it's used in contact investigations to test close contacts of people who have active TB disease. Second, it's used as part of targeted testing activities in various groups of people who are at high risk for TB, such as health care workers who serve high-risk clients, residents and employees of correctional facilities, and foreign-born people from areas that have a high TB incidence.
Who Gets Tested
Persons should get tested for TB by their doctor or local health department if they have spent time with a person known or suspected to have active TB disease; or have HIV infection or another condition that weakens the immune system and puts them at high risk for active TB disease; or have symptoms of active TB disease; or are from a country where active TB disease is common (most countries in Latin America, the Caribbean, Africa, Asia, Eastern Europe, and Russia); or live somewhere in the United States where active TB disease is more common such as a homeless shelter, migrant farm camp, prison or jail, or some nursing homes); or inject illegal drugs.2
Who Gives It
The Mantoux Tuberculin Skin Test should always be administered, read and interpreted by a designated, trained health care worker.2
How It's Given
There are three steps associated with the Mantoux Tuberculin Skin Test: administration, reading and interpretation which are explained in the How to Administer, Read and Interpret sections.
1 CDC. Mantoux Tuberculin Skin Test. Facilitator Guide. Available at http://www.cdc.gov/tb/education/mantoux/guide.htm. November 2013. Accessed April 7, 2015.
2 CDC. Testing for Tuberculosis (TB). Available at http://www.cdc.gov/tb/publications/factsheets/testing/tb_testing.htm. November 2011. Acessed April 29, 2015
Important Safety Information
Aplisol® is contraindicated in patients with known hypersensitivity or allergy to Aplisol® or any of its components. Aplisol® should not be administered to persons who have previously experienced a severe reaction to tuberculin purified protein derivative (e.g., vesiculation, ulceration, or necrosis) because of the severity of reaction that may occur at the test site. Strongly positive test reactions may result in scarring at the test site. Immediate erythematous or other reactions may occur at the injection site. Systemic allergic reactions including anaphylaxis/anaphylactoid reactions have been reported to occur in association with the use of Aplisol®. Several factors, such as certain types of infections, corticosteroids and immunosuppressants, malnutrition, and other various disease states and conditions have been reported to alter the ability to respond to the tuberculin test. A review of the patient's history with respect to possible immediate type hypersensitivity to the product, determination of previous use of Aplisol®, the presence of any contraindication, as well as potential factors that may alter results should be thoroughly conducted.
View the full Prescribing Information for Aplisol®